Korro Bio (KRRO) Expected to Announce Quarterly Earnings on Tuesday

Korro Bio (NASDAQ:KRRO) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect the company to announce earnings of ($1.93) per share and revenue of $0.4250 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Korro Bio (NASDAQ:KRRO) last posted its earnings results on Thursday, March 12th. The company reported ($5.32) EPS for the quarter, missing the consensus estimate of ($1.93) by ($3.39). The company had revenue of $1.29 million for the quarter, compared to the consensus estimate of $0.43 million. Korro Bio had a negative net margin of 1,834.48% and a negative return on equity of 115.95%. On average, analysts expect Korro Bio to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Korro Bio Stock Performance

Shares of Korro Bio stock opened at $10.40 on Monday. The stock has a market capitalization of $150.00 million, a price-to-earnings ratio of -0.83 and a beta of 2.98. Korro Bio has a twelve month low of $5.20 and a twelve month high of $55.89. The business’s 50 day simple moving average is $11.48 and its 200-day simple moving average is $18.96.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Wall Street Zen downgraded Korro Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Cantor Fitzgerald raised their target price on Korro Bio from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Friday, March 13th. Chardan Capital raised shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Thursday, January 29th. Raymond James Financial raised shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a report on Friday, March 13th. Finally, Clear Str upgraded shares of Korro Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.29.

Insider Transactions at Korro Bio

In other Korro Bio news, major shareholder Forest Baskett purchased 207,100 shares of Korro Bio stock in a transaction on Tuesday, March 10th. The stock was bought at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the transaction, the insider owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. The trade was a 18.99% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Anthony A. Jr. Florence purchased 207,100 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was acquired at an average cost of $11.11 per share, with a total value of $2,300,881.00. Following the purchase, the insider owned 1,297,893 shares of the company’s stock, valued at approximately $14,419,591.23. This represents a 18.99% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired 1,656,800 shares of company stock worth $18,407,048 over the last quarter. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Korro Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. bought a new position in Korro Bio in the 3rd quarter valued at about $39,000. Wells Fargo & Company MN increased its stake in Korro Bio by 45.5% during the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after buying an additional 2,352 shares during the period. Millennium Management LLC raised its position in shares of Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock worth $12,467,000 after buying an additional 4,650 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Korro Bio in the 3rd quarter worth approximately $340,000. Finally, Alliancebernstein L.P. acquired a new stake in shares of Korro Bio in the 3rd quarter worth approximately $369,000. 13.18% of the stock is currently owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.